The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Abstract
Purpose: Metastatic pancreatic ductal adenocarcinoma is characterized by excessive hyaluronan (HA) accumulation in the tumor microenvironment, elevating interstitial pressure and impairing perfusion. Preclinical studies demonstrated pegvorhyaluronidase alfa (PEGPH20) degrades HA, thereby increasing drug delivery. Patients and Methods: Patients with previously untreated metastatic pancreatic ductal adenocarcinoma were randomly assigned to treatment with PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) or nab-paclitaxel/gemcitabine (AG). Tumor HA levels were measured retrospectively using a novel affinity histochemistry assay. Primary end points were progression-free survival (PFS; overall) and thromboembolic (TE) event rate. Secondary end points included overall survival, PFS by HA level, and objective response rate. An early imbalance in TE events in the PAG arm led to a clinical hold; thereafter, patients with TE events were excluded and enoxaparin prophylaxis was initiated. Results: A total of 279 patients were randomly assigned; 246 had HA data; 231 were evaluable for efficacy; 84 (34%) had HA-high tumors (ie, extracellular matrix HA staining ≥ 50% of tumor surface at any intensity). PFS was significantly improved with PAG treatment overall (hazard ratio [HR], 0.73; 95% CI, 0.53 to 1.00; P = .049) and for patients with HA-high tumors (HR, 0.51; 95% CI, 0.26 to 1.00; P = .048). In patients with HA-high tumors (PAG v AG), the objective response rate was 45% versus 31%, and median overall survival was 11.5 versus 8.5 months (HR, 0.96; 95% CI, 0.57 to 1.61). The most common treatment-related grade 3/4 adverse events with significant differences between arms (PAG v AG) included muscle spasms (13% v 1%), neutropenia (29% v 18%), and myalgia (5% v 0%). TE events were comparable after enoxaparin initiation (14% PAG v 10% AG). Conclusion: This study met its primary end points of PFS and TE event rate. The largest improvement in PFS was observed in patients with HA-high tumors who received PAG. A similar TE event rate was observed between the treatment groups in stage 2 of the trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationProvenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Self-citationHyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Self-citationDesmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Whatcott, C. J., Diep, C. H., Jiang, P., Watanabe, A., LoBello, J., Sima, C., Hostetter, G., Shepard, H. M., Von Hoff, D. D., & Han, H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1051 · Cited by 645
Self-citationHingorani, S. R., Harris, W. P., Beck, J. T., Berdov, B. A., Wagner, S. A., Pshevlotsky, E. M., Tjulandin, S. A., Gladkov, O. A., Holcombe, R. F., Korn, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2010 · Cited by 333
Self-citationGemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Maraveyas, A., Waters, J., Roy, R., Fyfe, D., Propper, D., Lofts, F., Sgouros, J., Gardiner, E., Wedgwood, K., Ettelaie, C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.017 · Cited by 316
Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., Bookbinder, L. H., Li, X., Sugarman, B. J., Connor, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0470 · Cited by 298
Self-citationGuidance for the prevention and treatment of cancer-associated venous thromboembolism
Khorana, A. A., Carrier, M., Garcia, D. A., & Lee, A. Y. Y. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1313-4 · Cited by 210
Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis
Lyman, G. H., Eckert, L., Wang, Y., Wang, H., & Cohen, A. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0226 · Cited by 194
Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Singha, N. C., Nekoroski, T., Zhao, C., Symons, R. C., Jiang, P., Frost, G. I., Huang, Z., & Shepard, H. M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0580 · Cited by 149
Self-citationDuFort, C. C., DelGiorno, K. E., & Hingorani, S. R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.040 · Cited by 144
Self-citationTherapeutic options for the management of pancreatic cancer
Rossi, M. L., Rehman, A. A., & Gondi, C. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11142 · Cited by 141
Stromal reengineering to treat pancreas cancer
Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D., & Hingorani, S. R. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu115 · Cited by 130
Self-citationPhase II Trials in Journal of Clinical Oncology
Cannistra, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1811 · Cited by 103
Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic Approach to Cancer Therapy
Shepard, H. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00192 · Cited by 71
Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH
Khorana, A. A., Otten, H.-M., Zwicker, J. I., Connolly, G. C., Farge, D., & Pabinger, I. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12725 · Cited by 63
DelGiorno, K. E., Carlson, M. A., Osgood, R. J., Provenzano, P. P., Brockenbrough, J. S., Thompson, C. B., Shepard, H. M., Frost, G. I., Potter, J. D., & Hingorani, S. R. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.004 · Cited by 34
Self-citation
Research works printed but not linked: 1
- 10.6004/jnccn.2013.0163 · DOI
Cited by
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Self-citationTumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Diversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265
The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,287
Self-citation
Metadata
- Authors
- Hingorani, S. R., Zheng, L., Bullock, A. J., Seery, T. E., Harris, W. P., Sigal, D. S., Braiteh, F., Ritch, P. S., Zalupski, M. M., Bahary, N., Oberstein, P. E., Wang-Gillam, A., Wu, W., Chondros, D., Jiang, P., Khelifa, S., Pu, J., Aldrich, C., & Hendifar, A. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-02-01
- Volume
- 36
- Issue
- 4
- Pages
- 359-366
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2772923107
- Cited by
- 510
- References
- 20
- FWCI
- 20.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.